Antihyperglycemic therapy in type 2 diabetes

General recommendations

American Diabetes Association

Diabetes Care 2018
Diabetes Control and Complications Trial (DCCT)
Oral glucose tolerance test (OGTT)
Fasting plasma glucose (FPG) plasma glucose (PG)
National Glycohemoglobin Standardization Program (NGSP)
Glycemic Targets
 efficacy of the antihyperglycemic drug classes

Mean HbA1c reduction Efficacy category

Potential of >2% (>22 mmol/mol) Very high
>1–2% (>11–22 mmol/mol) High
>0.5–1% (>5.5–11 mmol/mol) Intermediate
≤0.5% (≤5.5 mmol/mol) Low
ANTIPLATELET AGENTS

➢Consider aspirin therapy (75–162 mg/day) as a primary

prevention strategy in those with type 1 or type 2 diabetes who are
at increased cardiovascular risk. This includes most men or women
aged >=50 years who have at least one additional major risk factor
(family history of ASCVD, hypertension, smoking, dyslipidemia, or
albuminuria) and are not at increased risk of bleeding

➢Use aspirin therapy (75–162mg/day) as a secondary prevention

strategy in those with diabetes and a history of atherosclerotic CVD